Clinical trial
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
NCT01272037 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- February 28, 2011
- Completion date
- January 8, 2027
- Enrollment
- 5,018 (actual)
- Sites
- 1,568
Conditions
As the registry lists them; a condition with its own page is linked.
breast ductal carcinoma in situ, invasive breast carcinoma, multicentric breast carcinoma, multifocal breast carcinoma, synchronous bilateral breast carcinoma